Literature DB >> 35507213

Diagnosis and Treatment of Small Renal Masses: Where Do We Stand?

Jerez Izquierdo Tamara1, Gómez Rivas Juan2, Zondervan Jeannelle Patricia3, Vives Dilme Roser2, Rodriguez Moisés4, Enikeev Dmitry5, Serrano Pascual Álvaro2, Moreno Sierra Jesús2.   

Abstract

PURPOSE OF REVIEW: To present an overview of the current evidence-based studies covering diagnostic and management of SRM. RECENT
FINDINGS: Renal cell carcinoma (RCC) represents 3% of the cancers. Nowadays, partial nephrectomy (PN) represents gold standard treatment. New nephron-sparing approaches such as active surveillance and ablative therapies have been increasingly used as an alternative to surgical intervention. Due to novel comprehension of RCC and widespread use of imaging techniques, diagnosis at early stage in elderly patients has increased. Treatment decision-making should be based on patient and tumour characteristics. With expanding treatment options, the management of SRMs has become a debate and should be adjusted to patient and tumour characteristics. In a shared decision manner, both active surveillance with possible delayed intervention and focal therapy should be discussed with the patient as an alternative to partial nephrectomy.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Mesh:

Year:  2022        PMID: 35507213     DOI: 10.1007/s11934-022-01093-x

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  40 in total

1.  Subtype differentiation of small renal cell carcinomas on three-phase MDCT: usefulness of the measurement of degree and heterogeneity of enhancement.

Authors:  Seung Chai Jung; Jeong Yeon Cho; Seung Hyup Kim
Journal:  Acta Radiol       Date:  2011-11-23       Impact factor: 1.990

2.  Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter.

Authors:  Mesut Remzi; Mehmet Ozsoy; Hans-Christoph Klingler; Martin Susani; Matthias Waldert; Christian Seitz; Joerg Schmidbauer; Michael Marberger
Journal:  J Urol       Date:  2006-09       Impact factor: 7.450

3.  Rising incidence of small renal masses: a need to reassess treatment effect.

Authors:  John M Hollingsworth; David C Miller; Stephanie Daignault; Brent K Hollenbeck
Journal:  J Natl Cancer Inst       Date:  2006-09-20       Impact factor: 13.506

4.  Renal nephrometry score is associated with urine leak after partial nephrectomy.

Authors:  Bryan Bruner; Rodney H Breau; Christine M Lohse; Bradley C Leibovich; Michael L Blute
Journal:  BJU Int       Date:  2010-11-18       Impact factor: 5.588

5.  Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis.

Authors:  John M Hollingsworth; David C Miller; Stephanie Daignault; Brent K Hollenbeck
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

6.  Comparison of accuracy of 14-, 18- and 20-G needles in ex-vivo renal mass biopsy: a prospective, blinded study.

Authors:  Alberto Breda; Eric G Treat; Leah Haft-Candell; John T Leppert; Jonathan D Harper; Jonathan Said; Steven Raman; Robert B Smith; Arie S Belldegrun; Peter G Schulam
Journal:  BJU Int       Date:  2009-11-02       Impact factor: 5.588

7.  Time trends in the incidence of renal carcinoma: analysis of Connecticut Tumor Registry data, 1935-1989.

Authors:  D L Katz; T Zheng; T R Holford; J Flannery
Journal:  Int J Cancer       Date:  1994-07-01       Impact factor: 7.396

8.  Solid renal tumors: an analysis of pathological features related to tumor size.

Authors:  Igor Frank; Michael L Blute; John C Cheville; Christine M Lohse; Amy L Weaver; Horst Zincke
Journal:  J Urol       Date:  2003-12       Impact factor: 7.450

9.  Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model.

Authors:  Alexander Kutikov; Brian L Egleston; Daniel Canter; Marc C Smaldone; Yu-Ning Wong; Robert G Uzzo
Journal:  J Urol       Date:  2012-10-18       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.